Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Luminal A, B, and basal subtypes each comprise approximately 30% of all localized nonmetastatic prostate cancer cases, says Hamid. The population included the phase III CHAARTED trial consisted largely of patients with luminal B and basal tumors. In a correlative study from the CHAARTED trial, investigators found that luminal B tumors were associated with a shorter survival on hormone therapy alone, but those with that subtype significantly benefited from up-front docetaxel, says Hamid.

Conversely, basal tumors were associated with a better prognosis compared with luminal B tumors. However, patients with basal tumors did not derive a significant benefit with up-front docetaxel, says Hamid. This research suggests that luminal B and basal subtypes have prognostic value and predictive potential, concludes Hamid.